Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer

Autor: Sara SF Al‐Badran, Lauren Grant, Maejoy V Campo, Jitwadee Inthagard, Kathryn Pennel, Jean Quinn, Prakash Konanahalli, Liam Hayman, Paul G Horgan, Donald C McMillan, Campbell SD Roxburgh, Antonia Roseweir, James H Park, Joanne Edwards

Publikováno v: The Journal of Pathology: Clinical Research, Vol 7, Iss 2, Pp 121-134 (2021)

Abstract The tumour microenvironment is an important factor for colorectal cancer prognosis, affecting the patient's immune response. Immune checkpoints, which regulate the immune functions of lymphocytes, may provide prognostic power. This study aim

Externí odkaz: https://doaj.org/article/a3ff5f9d8dbd4c0faf511ffc1822eba4

Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome

Autor: Mineui Hong, Jeong Won Kim, Min Kyoon Kim, Soo Kyung Ahn, Bong Wha Chung

Publikováno v: Journal of Cancer

Purpose: The programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays an important role in antitumor immune responses. However, there is considerable inconsistency regarding the prognostic value of PD-L1 expression status in b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221cf6a15222bc1c9823fc89ae0e8e25
https://pubmed.ncbi.nlm.nih.gov/33193888

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.

Autor: Al-Badran SS; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Grant L; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Campo MV; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Inthagard J; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Pennel K; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Quinn J; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Konanahalli P; Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK., Hayman L; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Horgan PG; Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK., McMillan DC; Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK., Roxburgh CS; Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK., Roseweir A; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK., Park JH; Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK., Edwards J; Unit of Experimental Therapeutics, Institute of Cancer Sciences, Wolfson-Wohl Cancer Research Centre, Glasgow, UK.

Publikováno v: The journal of pathology. Clinical research [J Pathol Clin Res] 2021 Mar; Vol. 7 (2), pp. 121-134. Date of Electronic Publication: 2020 Dec 18.